Shots:
- China’s NMPA has approved Sycume for the treatment of thyroid eye disease (TED)
- Approval was based on P-III (RESTORE-1) trial in TED pts, which met its 1EP in 2024, with 85.8% pts achieving ≥2mm proptosis reduction at 24wks., along with improved inflammation & QoL; data was presented at WOC, CSE, and CCOS
- Sycume (teprotumumab N01) blocks IGF-1R signalling to reduce inflammatory factor expression & hyaluronic acid synthesis, along with other glycosaminoglycans synthesis from OFs activation. It also prevents OF differentiation into adipocytes/myofibroblasts to lower disease activity & improve symptoms such as proptosis, diplopia, orbital congestion, & edema
Ref: Prnewswire | Image: Innovent
Related News:- Innovent Reports the NMPA’s NDA Acceptance & Priority Review of Neoadjuvant Ipilimumab + Sintilimab for Colon Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
